Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

This program is in place for prescriptions of cyclosporine ophthalmic solution 0.1% (VEVYE, Harrow) and promises a $59 price tag per bottle, effective immediately.

Harrow launches partnership with mail-order pharmacy, PhilRx to expand access to VEVYE

The Perimeter B-Series OCT system combines proprietary AI technology with optical coherence tomography, for use during breast-conserving surgeries. 

Perimeter submits Premarket Approval application with FDA for Perimeter B-Series OCT system

The ReNEW study for dry AMD is evaluating the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide, a first-in-class mitochondria-targeted investigational therapeutic.

Stealth BioTherapeutics reaches 50 percent enrollment target in phase 3 ReNEW study

The findings of this model support KIO-104 as a promising therapeutic candidate for both the prevention and treatment of PVR.

Preclinical study of KIO-104 in a proliferative vitreoretinopathy model accepted for poster presentation at ARVO 2025

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times - Ophthalmology news, articles, and events

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

-Bausch & Lomb (B&L) has named Efrain Rivera senior vice president and chief financial officer, succeeding Stephen C. McCluski, who has announced his retirement effective June 30.  

Rochester, NY?Bausch & Lomb (B&L) has named Efrain Rivera senior vice president and chief financial officer, succeeding Stephen C. McCluski, who has announced his retirement effective June 30.

B&L appoints Rivera to succeed McCluski